Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Partner Highlight Connecting Patients with Innovative Immunotherapies Our Impact, Partner Highlight All the Right Ingredients: The Founders of ArsenalBio Partner Highlight, Press Release NanoString and PICI Partner to Optimize Cell Therapies Announcement, Research Update Five Key Takeaways from ASCO 2021 Cancer Research Heroes, Patient Story When Cancer Becomes A Calling: Lacey Kitch Research Project Pancreatic Cancer Program